Close
American Drug Delivery & Formulation Summit
Xylem

Business & Industry

Novartis and Antares Therapeutics Form Strategic Partnership for Cancer Drug Development

Novartis has finalized a significant collaboration agreement with Antares Therapeutics to advance the discovery and development of small molecule therapies for various cancers. The deal, which could reach a total value of $1.9 billion, focuses on addressing oncology targets...

Abu Dhabi and MSD Partner to Enhance Healthcare Access via New Logistics Hub

The Department of Health โ€“ Abu Dhabi (DoH) has announced a strategic collaboration with MSD to evaluate the feasibility of establishing an Abu Dhabi logistics hub. Located within the Health, Endurance, Longevity, and Medicine (HELM) Cluster, this planned facility...

Bayer and Iambic Collaboration Expands AI Drug Discovery Efforts

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuseโ€™s lead asset, PER-001,...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI platform designed to help close care gaps and improve the identification of untreated and under-treated patients with difficult-to-diagnose conditions, has entered into a collaboration agreement with Sanofi. Under the arrangement,...

Lilly and BioArctic Partner on BrainTransporter Technology

Eli Lilly and Company has entered into a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to advance a potential treatment for neurodegenerative diseases. Under the arrangement, the companies will combine BioArcticโ€™s BrainTransporter Technology with an undisclosed Lilly...

AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal

In a significant expansion of its research and development capabilities, a definitive agreement has been reached where AbbVie acquires Apogee Therapeutics for $10.9 billion. This strategic transaction is centered around the addition of zumilokibart, a highly anticipated IL-13 antibody,...

Insilico Medicine Advances ISM8969 Into Phase 1 Trial as Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation

Insilico Medicine has reached a significant clinical milestone with the completion of first-in-human dosing of ISM8969 in a Phase 1 study. Conducted in collaboration with Hygtia Therapeutics, the ISM8969 Phase 1 trial marks the transition of this oral, brain-penetrant...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป